Alzheimer s DiseaseAD Alzheimer'NCT07673263
Effects of X Box Kinect 360 in Alzheimer's Disease
A study testing 3D Kinect based game and Conventional therapy group in people with Alzheimer s Disease, run by Ziauddin University at 1 site in Pakistan.
Trial summary
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78… Read more about this study
- Who is it for?
- Ages 50 to 85 years
- Conditions the study is for
- Alzheimer s Disease
- What is being tested?
- 3D Kinect based game and Conventional therapy group
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 38 participants
- Where
- 1 sitePakistan
- Study dates
- 24 Jun 2026to 15 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Alzheimer's disease of age between 50-85 years.
- Diagnosed AD stage Mild to Moderate.
Who cannot join
- Undiagnosed AD patients.
- Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site
Ziauddin University
Karachi, Sindhi
Silvia Peter William, Mphil, 021-36629251 ext. 5, williamsilviapeter@gmail.com
About this study
Official title: Effect of 3D Kinect Games With Google Cardboard on Motor Control, Cognition, and Quality of Life in Mild to Moderate Alzheimer's Patient
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).
Read the detailed description
In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level. In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023). Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017). Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe. A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).
- Conditions
- Alzheimer s Disease
- Being tested
- 3D Kinect based game, Conventional therapy group
- Keywords
- Alzheimer Disease, Virtual Reality, Kinect xbox 360
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
3D Kinect based gameOther
Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.
Conventional therapy groupOther
The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025). The patients will take 1-2 minutes rest after 5 minutes of activity. Rest periods of 1-2 minutes after every 5 minutes of activity.
| Study group | Role | What they receive |
|---|---|---|
| Arms 1 | Experimental | Arm Description: Game-Based Rehabilitation received total 30sessions, 30 minutes/session, 5 times/week for total 6 weeks. Receives: Other: 3D Kinect based game |
| Arm 2 | Placebo comparator | Arm Description: Conventional Rehabilitation received total 30 sessions, 30 minutes/session, 5 times/week for total 6 weeks. Receives: Other: Conventional therapy group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognition
Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability.
Measured: Baseline
Cognition
Cognitive function will be assessed through Mini- Cog among Mild to Moderate AD patients where low values indicate decrease cognitive function
Measured: After 6 week of Intervention
Motor Function
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility
Measured: Baseline
Motor Function
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate functional mobility
Measured: After 6 week of intervention
Quality of Life (QOL)
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
Measured: Baseline
Quality Of Life (QOL)
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
Measured: After 6 weeks of Intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2026
- Study start24 Jun 2026 (estimated)
- Primary completion15 Jul 2026 (estimated)
- Study completion15 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Alzheimer s DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Experimental Group Kinect game-based Rehabilitation: Device Kinect XBOX 360. Kinect game will be given 30 sessions, and intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks, The patients will take 1-2 minutes rest after 5 minutes of activity. Placebo Comparator: Control Group: Conventional Rehabilitation: Conventional exercises will be given 30 sessions, and intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks, The patients will take 1-2 minutes rest after 5 minutes of activity.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ziauddin University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Silvia Peter William, MPhil, Principal investigator, Ziauddin University, Karachi, Sindh, Pakistan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07673263
- Sponsor's protocol ID
- 11691225SPREH
- Other IDs
- 11691225SPREH
- Acronym
- AD Alzheimer'
- Status last verified
- Jun 2026
- First submitted
- 23 Jun 2026
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cox KL, Clare L, Cyarto EV, Ellis KA, Etherton-Beer C, Southam J, Ames D, Flicker L, Almeida OP, LoGiudice D, Liew D, Vlaskovsky P, Lautenschlager NT. A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. J Alzheimers Dis. 2021;84(1):207-226. doi: 10.3233/JAD-210479.
PubMed 34511499Cousi C, Igier V, Quintard B. French cross-cultural adaptation and validation of the Quality of Life-Alzheimer's Disease scale in Nursing Homes (QOL-AD NH). Health Qual Life Outcomes. 2021 Sep 15;19(1):219. doi: 10.1186/s12955-021-01853-2.
PubMed 34526034Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo NJ. Advances in Alzheimer's disease's pharmacological treatment. Front Pharmacol. 2023 Jan 26;14:1101452. doi: 10.3389/fphar.2023.1101452. eCollection 2023.
PubMed 36817126Chen C, Homma A, Mok VC, Krishnamoorthy E, Alladi S, Meguro K, Abe K, Dominguez J, Marasigan S, Kandiah N, Kim SY, Lee DY, De Silva HA, Yang YH, Pai MC, Senanarong V, Dash A. Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region. J Intern Med. 2016 Oct;280(4):359-74. doi: 10.1111/joim.12495. Epub 2016 Mar 16.
PubMed 26992016Cezar NOC, Ansai JH, de Andrade LP. Home-based multimodal exercise program in older people with Alzheimer disease: Randomized controlled trial protocol. Physiother Res Int. 2021 Apr;26(2):e1899. doi: 10.1002/pri.1899. Epub 2021 Feb 15.
PubMed 33586858Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003 Oct;51(10):1451-4. doi: 10.1046/j.1532-5415.2003.51465.x.
PubMed 145111672023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14.
PubMed 36918389Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith C. Introducing virtual reality therapy for inpatients with dementia admitted to an acute care hospital: learnings from a pilot to pave the way to a randomized controlled trial. Pilot Feasibility Stud. 2020 Oct 31;6(1):166. doi: 10.1186/s40814-020-00708-9.
PubMed 33292729Ries JD, Hutson J, Maralit LA, Brown MB. Group Balance Training Specifically Designed for Individuals With Alzheimer Disease: Impact on Berg Balance Scale, Timed Up and Go, Gait Speed, and Mini-Mental Status Examination. J Geriatr Phys Ther. 2015 Oct-Dec;38(4):183-93. doi: 10.1519/JPT.0000000000000030.
PubMed 25621384Amjad I, Toor H, Niazi IK, Pervaiz S, Jochumsen M, Shafique M, Haavik H, Ahmed T. Xbox 360 Kinect Cognitive Games Improve Slowness, Complexity of EEG, and Cognitive Functions in Subjects with Mild Cognitive Impairment: A Randomized Control Trial. Games Health J. 2019 Apr;8(2):144-152. doi: 10.1089/g4h.2018.0029. Epub 2018 Sep 21.
PubMed 30239213
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of 3D Kinect Games With Google Cardboard on Motor Control, Cognition, and Quality of Life in Mild to Moderate Alzheimer's Patient
- ClinicalTrials.gov ID
- NCT07673263
- Acronym / sponsor ID
- AD Alzheimer' / 11691225SPREH
- Conditions
- Alzheimer s Disease
- Keywords
- Alzheimer Disease, Virtual Reality, Kinect xbox 360
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- Ziauddin UniversityUniversity, hospital or other
- Study start
- 24 Jun 2026 (estimated)
- Primary completion
- 15 Jul 2026 (estimated)
- Study completion
- 15 Aug 2026 (estimated)
- First posted
- 29 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).
Detailed description
In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level. In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023). Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017). Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe. A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Experimental Group Kinect game-based Rehabilitation: Device Kinect XBOX 360. Kinect game will be given 30 sessions, and intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks, The patients will take 1-2 minutes rest after 5 minutes of activity. Placebo Comparator: Control Group: Conventional Rehabilitation: Conventional exercises will be given 30 sessions, and intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks, The patients will take 1-2 minutes rest after 5 minutes of activity.
| Arm | Type | Receives |
|---|---|---|
| Arms 1 | Experimental | Other: 3D Kinect based gameArm Description: Game-Based Rehabilitation received total 30sessions, 30 minutes/session, 5 times/week for total 6 weeks. |
| Arm 2 | Placebo comparator | Other: Conventional therapy groupArm Description: Conventional Rehabilitation received total 30 sessions, 30 minutes/session, 5 times/week for total 6 weeks. |
Who may qualify
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Alzheimer's disease of age between 50-85 years.
- Diagnosed AD stage Mild to Moderate.
Key exclusion criteria (2 listed)
- Undiagnosed AD patients.
- Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 3D Kinect based gameExperimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks. | Other | Arms 1 |
| Conventional therapy groupThe intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025). The patients will take 1-2 minutes rest after 5 minutes of activity. Rest periods of 1-2 minutes after every 5 minutes of activity. | Other | Arm 2 |
Primary outcome
Cognition
Time frame: Baseline
Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability.
Cognition
Time frame: After 6 week of Intervention
Cognitive function will be assessed through Mini- Cog among Mild to Moderate AD patients where low values indicate decrease cognitive function
Motor Function
Time frame: Baseline
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility
Motor Function
Time frame: After 6 week of intervention
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate functional mobility
Quality of Life (QOL)
Time frame: Baseline
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
Quality Of Life (QOL)
Time frame: After 6 weeks of Intervention
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Results publication: PubMed 34511499Cox KL, Clare L, Cyarto EV, Ellis KA, Etherton-Beer C, Southam J, Ames D, Flicker L, Almeida OP, LoGiudice D, Liew D, Vlaskovsky P, Lautenschlager NT. A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. J Alzheimers Dis. 2021;84(1):207-226. doi: 10.3233/JAD-210479.
- Results publication: PubMed 34526034Cousi C, Igier V, Quintard B. French cross-cultural adaptation and validation of the Quality of Life-Alzheimer's Disease scale in Nursing Homes (QOL-AD NH). Health Qual Life Outcomes. 2021 Sep 15;19(1):219. doi: 10.1186/s12955-021-01853-2.
- Results publication: PubMed 36817126Conti Filho CE, Loss LB, Marcolongo-Pereira C, Rossoni Junior JV, Barcelos RM, Chiarelli-Neto O, da Silva BS, Passamani Ambrosio R, Castro FCAQ, Teixeira SF, Mezzomo NJ. Advances in Alzheimer's disease's pharmacological treatment. Front Pharmacol. 2023 Jan 26;14:1101452. doi: 10.3389/fphar.2023.1101452. eCollection 2023.
- Results publication: PubMed 26992016Chen C, Homma A, Mok VC, Krishnamoorthy E, Alladi S, Meguro K, Abe K, Dominguez J, Marasigan S, Kandiah N, Kim SY, Lee DY, De Silva HA, Yang YH, Pai MC, Senanarong V, Dash A. Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region. J Intern Med. 2016 Oct;280(4):359-74. doi: 10.1111/joim.12495. Epub 2016 Mar 16.
- Results publication: PubMed 33586858Cezar NOC, Ansai JH, de Andrade LP. Home-based multimodal exercise program in older people with Alzheimer disease: Randomized controlled trial protocol. Physiother Res Int. 2021 Apr;26(2):e1899. doi: 10.1002/pri.1899. Epub 2021 Feb 15.
- Results publication: PubMed 14511167Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003 Oct;51(10):1451-4. doi: 10.1046/j.1532-5415.2003.51465.x.
- Results publication: PubMed 369183892023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14.
- Results publication: PubMed 33292729Appel L, Kisonas E, Appel E, Klein J, Bartlett D, Rosenberg J, Smith C. Introducing virtual reality therapy for inpatients with dementia admitted to an acute care hospital: learnings from a pilot to pave the way to a randomized controlled trial. Pilot Feasibility Stud. 2020 Oct 31;6(1):166. doi: 10.1186/s40814-020-00708-9.
- Results publication: PubMed 25621384Ries JD, Hutson J, Maralit LA, Brown MB. Group Balance Training Specifically Designed for Individuals With Alzheimer Disease: Impact on Berg Balance Scale, Timed Up and Go, Gait Speed, and Mini-Mental Status Examination. J Geriatr Phys Ther. 2015 Oct-Dec;38(4):183-93. doi: 10.1519/JPT.0000000000000030.
- Results publication: PubMed 30239213Amjad I, Toor H, Niazi IK, Pervaiz S, Jochumsen M, Shafique M, Haavik H, Ahmed T. Xbox 360 Kinect Cognitive Games Improve Slowness, Complexity of EEG, and Cognitive Functions in Subjects with Mild Cognitive Impairment: A Randomized Control Trial. Games Health J. 2019 Apr;8(2):144-152. doi: 10.1089/g4h.2018.0029. Epub 2018 Sep 21.
- Individual participant dataSharing planned: No
Related trials for Alzheimer s Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Not yet recruitingObservational study
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
RecruitingObservational study
Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)
Stroke, Alzheimer s Disease
RecruitingPhase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Alzheimer s Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Silvia Peter William, MPhil principal investigator
Ziauddin University, Karachi, Sindh, Pakistan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 3D Kinect based game and Conventional therapy group in people with Alzheimer s Disease, run by Ziauddin University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Silvia Peter William, Mphil (021-36629251 ext. 5, williamsilviapeter@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognition (time frame: Baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07673263, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.